The present invention relates to salts of compounds represented by formula (I). The salt is a crystalline or amorphous phosphate, or a crystalline or amorphous oxalate. In particular, the phosphate crystal form B of the present invention has high crystallinity, low hygroscopicity and good stability, has an excellent oral bioavailability of the phosphate crystal form B, and is used for long-term administration. It has good resistance, is less likely to induce hypoglycemia, and has an excellent inhibitory effect on serum DPPIV. [Chemical formula 1] [Selection diagram] Fig. 4本発明は、式（Ｉ）に示す化合物の塩に関する。前記塩は結晶形態もしくは非晶質形態のリン酸塩、または結晶形態もしくは非晶質形態のシュウ酸塩である。特に、本発明のリン酸塩の結晶型Ｂは、高い結晶度、低い吸湿性及び良好な安定性を有し、リン酸塩の結晶型Ｂの経口生体利用率が優れ、長期投与する場合、良好な耐性を有し、低血糖を誘発しにくく、血清ＤＰＰＩＶに対する阻害効果に優れる。【化１】【選択図】図４
